Verisante Revises LOI for China Rights to Cancer Diagnostic Device

Verisante Technology of Canada has reworked the terms of a Letter of Intent with an unnamed partner for global/China rights to its cancer detection technology. Under the new agreement, the rights to the technology will be placed in an LLC, which will be listed as soon as possible on Shenzhen's OTC stock exchange to raise additional capital. Verisante will own 30% of the LLC. The LLC will own worldwide rights to commercialize Verisante's Core™ Raman technology and ClearVu endoscopic system to detect lung cancer and China rights to other Core products. The partner will make a $2.15 million investment in Verisante. More details.... Stock Symbols: (TSX: VRS; OTCQX: VRSEF) Share this with colleagues: // //